Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-744 in Relapsed/Refractory AML
NCT03360006Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABBV-744 in acute myeloid leukemia (AML) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration, Time to Cmax and 6 more. Started Mar 2018; status: terminated.
02
Drugs
ABBV-744
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03360006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360006.